InvestSMART

Neurizon Therapeutics Limited (ASX:NUZ)

ALERT: Price-sensitive ASX Announcement for NUZ
Current share price for NUZ : $0.069 0.006 (9.52%)+
Announcement
Release
17 Jun 2026 9:07AM
Price at Release
$0.063
Full Release
download
Summary
Neurizon Therapeutics Limited has executed a strategic long-term supply agreement with Elanco Animal Health to secure access to GMP monepantel, the active pharmaceutical ingredient in Neurizon's lead asset, NUZ-001. This agreement marks a significant milestone in the company's journey towards commercialization, particularly for its potential treatment for Amyotrophic Lateral Sclerosis (ALS). The agreement supports Neurizon's Phase 2/3 clinical development and commercial readiness by ensuring long-term manufacturing and supply chain stability. It further strengthens Neurizon's position as a leader in neurodegenerative disease treatment development, enhancing its regulatory and Chemistry, Manufacturing and Controls (CMC) infrastructure. The contract, which has an initial term of five years, includes specific provisions related to forecasting, production scheduling, and confidentiality among others, thereby reinforcing Neurizon's strategic commercial framework.
Key Points
  • Neurizon executes long-term supply agreement with Elanco.
  • Agreement provides access to GMP monepantel for NUZ-001.
  • Represents a major milestone in commercialisation readiness.
  • Strengthens long-term manufacturing and supply framework.
  • Supports operational scalability post-Phase 2/3 program.
  • Neurizon focuses on neurodegenerative disease treatments.
  • Enhances regulatory and CMC infrastructure.
  • Initial term of five years with specific provisions included.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.